TLN2
Talin-2
Also known as: ILWEQ, KIAA0320, TLN2_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9Y4G6
- Gene
- TLN2
- Ensembl
- ENSG00000171914
- Chromosome
- 15
- Canonical length
- 2542 aa
- Protein class
- Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Focal adhesion sites,Cytosol
OverviewNCBI Gene
This gene encodes a protein related to talin 1, a cytoskeletal protein that plays a significant role in the assembly of actin filaments and in spreading and migration of various cell types, including fibroblasts and osteoclasts. This protein has a different pattern of expression compared to talin 1 but, like talin 1, is thought to associate with unique transmembrane receptors to form novel linkages between extracellular matrices and the actin cytoskeleton. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
2542 residues, UniProt reviewed canonical sequence.
>Q9Y4G6|TLN2
1 MVALSLKICV RHCNVVKTMQ FEPSTAVYDA CRVIRERVPE AQTGQASDYG LFLSDEDPRK
61 GIWLEAGRTL DYYMLRNGDI LEYKKKQRPQ KIRMLDGSVK TVMVDDSKTV GELLVTICSR
121 IGITNYEEYS LIQETIEEKK EEGTGTLKKD RTLLRDERKM EKLKAKLHTD DDLNWLDHSR
181 TFREQGVDEN ETLLLRRKFF YSDQNVDSRD PVQLNLLYVQ ARDDILNGSH PVSFEKACEF
241 GGFQAQIQFG PHVEHKHKPG FLDLKEFLPK EYIKQRGAEK RIFQEHKNCG EMSEIEAKVK
301 YVKLARSLRT YGVSFFLVKE KMKGKNKLVP RLLGITKDSV MRVDEKTKEV LQEWPLTTVK
361 RWAASPKSFT LDFGEYQESY YSVQTTEGEQ ISQLIAGYID IILKKKQSKD RFGLEGDEES
421 TMLEESVSPK KSTILQQQFN RTGKAEHGSV ALPAVMRSGS SGPETFNVGS MPSPQQQVMV
481 GQMHRGHMPP LTSAQQALMG TINTSMHAVQ QAQDDLSELD SLPPLGQDMA SRVWVQNKVD
541 ESKHEIHSQV DAITAGTASV VNLTAGDPAD TDYTAVGCAI TTISSNLTEM SKGVKLLAAL
601 MDDEVGSGED LLRAARTLAG AVSDLLKAVQ PTSGEPRQTV LTAAGSIGQA SGDLLRQIGE
661 NETDERFQDV LMSLAKAVAN AAAMLVLKAK NVAQVAEDTV LQNRVIAAAT QCALSTSQLV
721 ACAKVVSPTI SSPVCQEQLI EAGKLVDRSV ENCVRACQAA TTDSELLKQV SAAASVVSQA
781 LHDLLQHVRQ FASRGEPIGR YDQATDTIMC VTESIFSSMG DAGEMVRQAR VLAQATSDLV
841 NAMRSDAEAE IDMENSKKLL AAAKLLADST ARMVEAAKGA AANPENEDQQ QRLREAAEGL
901 RVATNAAAQN AIKKKIVNRL EVAAKQAAAA ATQTIAASQN AAVSNKNPAA QQQLVQSCKA
961 VADHIPQLVQ GVRGSQAQAE DLSAQLALII SSQNFLQPGS KMVSSAKAAV PTVSDQAAAM
1021 QLSQCAKNLA TSLAELRTAS QKAHEACGPM EIDSALNTVQ TLKNELQDAK MAAVESQLKP
1081 LPGETLEKCA QDLGSTSKAV GSSMAQLLTC AAQGNEHYTG VAARETAQAL KTLAQAARGV
1141 AASTTDPAAA HAMLDSARDV MEGSAMLIQE AKQALIAPGD AERQQRLAQV AKAVSHSLNN
1201 CVNCLPGQKD VDVALKSIGE SSKKLLVDSL PPSTKPFQEA QSELNQAAAD LNQSAGEVVH
1261 ATRGQSGELA AASGKFSDDF DEFLDAGIEM AGQAQTKEDQ IQVIGNLKNI SMASSKLLLA
1321 AKSLSVDPGA PNAKNLLAAA ARAVTESINQ LITLCTQQAP GQKECDNALR ELETVKGMLD
1381 NPNEPVSDLS YFDCIESVME NSKVLGESMA GISQNAKTGD LPAFGECVGI ASKALCGLTE
1441 AAAQAAYLVG ISDPNSQAGH QGLVDPIQFA RANQAIQMAC QNLVDPGSSP SQVLSAATIV
1501 AKHTSALCNA CRIASSKTAN PVAKRHFVQS AKEVANSTAN LVKTIKALDG DFSEDNRNKC
1561 RIATAPLIEA VENLTAFASN PEFVSIPAQI SSEGSQAQEP ILVSAKTMLE SSSYLIRTAR
1621 SLAINPKDPP TWSVLAGHSH TVSDSIKSLI TSIRDKAPGQ RECDYSIDGI NRCIRDIEQA
1681 SLAAVSQSLA TRDDISVEAL QEQLTSVVQE IGHLIDPIAT AARGEAAQLG HKVTQLASYF
1741 EPLILAAVGV ASKILDHQQQ MTVLDQTKTL AESALQMLYA AKEGGGNPKA QHTHDAITEA
1801 AQLMKEAVDD IMVTLNEAAS EVGLVGGMVD AIAEAMSKLD EGTPPEPKGT FVDYQTTVVK
1861 YSKAIAVTAQ EMMTKSVTNP EELGGLASQM TSDYGHLAFQ GQMAAATAEP EEIGFQIRTR
1921 VQDLGHGCIF LVQKAGALQV CPTDSYTKRE LIECARAVTE KVSLVLSALQ AGNKGTQACI
1981 TAATAVSGII ADLDTTIMFA TAGTLNAENS ETFADHRENI LKTAKALVED TKLLVSGAAS
2041 TPDKLAQAAQ SSAATITQLA EVVKLGAASL GSDDPETQVV LINAIKDVAK ALSDLISATK
2101 GAASKPVDDP SMYQLKGAAK VMVTNVTSLL KTVKAVEDEA TRGTRALEAT IECIKQELTV
2161 FQSKDVPEKT SSPEESIRMT KGITMATAKA VAAGNSCRQE DVIATANLSR KAVSDMLTAC
2221 KQASFHPDVS DEVRTRALRF GTECTLGYLD LLEHVLVILQ KPTPEFKQQL AAFSKRVAGA
2281 VTELIQAAEA MKGTEWVDPE DPTVIAETEL LGAAASIEAA AKKLEQLKPR AKPKQADETL
2341 DFEEQILEAA KSIAAATSAL VKSASAAQRE LVAQGKVGSI PANAADDGQW SQGLISAARM
2401 VAAATSSLCE AANASVQGHA SEEKLISSAK QVAASTAQLL VACKVKADQD SEAMRRLQAA
2461 GNAVKRASDN LVRAAQKAAF GKADDDDVVV KTKFVGGIAQ IIAAQEEMLK KERELEEARK
2521 KLAQIRQQQY KFLPTELRED EGLocalizationUniProt · AlphaFold · HPA
Whether an antibody against TLN2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.27
- Highest tissue expression
- 35 nTPM
Expression across tissuesHPA
Tissue
- kidney: 35 nTPM
- skeletal muscle: 24 nTPM
- cerebral cortex: 23 nTPM
- adipose tissue: 18 nTPM
- choroid plexus: 17 nTPM
- spinal cord: 14 nTPM
Single-cell type
- adipocytes: 1,150 nCPM
- choroid plexus epithelial cells: 1,035 nCPM
- myosatellite cells: 716 nCPM
- ependymal cells: 714 nCPM
- microglia: 570 nCPM
- fibro-adipogenic progenitors: 475 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- choroid plexus: 73 nTPM
- cerebral cortex: 67 nTPM
- basal ganglia: 61 nTPM
- white matter: 57 nTPM
- spinal cord: 54 nTPM
- midbrain: 48 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.28
- gnomAD pLI
- 0.99
- gnomAD missense Z
- 1.41
- DepMap mean gene effect
- -0.06
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- actin cytoskeleton organization
- cell adhesion
- cell-cell adhesion
- cell-cell junction assembly
- presynaptic actin cytoskeleton organization
Molecular functions
- actin binding
- actin filament binding
- integrin binding
- structural constituent of cytoskeleton
- structural molecule activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- FERM domain
- IRS-type PTB domain
- I/LWEQ domain
- PH-like domain superfamily
- FERM/acyl-CoA-binding protein superfamily
- Vinculin-binding site-containing domain
- Talin, central
- FERM, N-terminal
- FERM conserved site
- FERM central domain
- Band 4.1 domain
- Ubiquitin-like domain superfamily
- Talin, N-terminal F0 domain
- FERM superfamily, second domain
- I/LWEQ domain superfamily
- Talin, central domain superfamily
- Alpha-catenin/vinculin-like superfamily
- Talin-1/2, rod-segment
- Talin, R4 domain
- Talin 1-like, rod-segment domain
- Talin, IBS2B domain
- Talin-1/2, VBS2 domain
- I/LWEQ domain
- PTB domain (IRS-1 type)
- Vinculin Binding Site
- Talin, middle domain
- FERM N-terminal domain
- N-terminal or F0 domain of Talin-head FERM
- Talin, R4 domain
- Talin 1-like, rod segment domain
- Talin IBS2B domain
- Talin VBS2 domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of TLN2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TLN2 as an antibody target. Whether an autoantibody or antibody against TLN2 could matter depends on whether native TLN2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TLN2 is annotated at the cell surface, where native TLN2 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label TLN2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...